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Resistance mechanisms and 
population structure of highly drug 
resistant Klebsiella in pakistan 
during the introduction of the 
carbapenemase NDM-1
eva Heinz  1, Hasan ejaz  2,3,4, Josefin Bartholdson scott5, Nancy Wang  3, shruti Gujaran3, 
Derek pickard1, Jonathan Wilksch3, Hanwei Cao3, Ikram-ul Haq6, Gordon Dougan1,5 & 
Richard A. strugnell  3
Klebsiella pneumoniae is a major threat to public health with the emergence of isolates resistant to 
most, if not all, useful antibiotics. We present an in-depth analysis of 178 extended-spectrum beta-
lactamase (esBL)-producing K. pneumoniae collected from patients resident in a region of pakistan, 
during the period 2010–2012, when the now globally-distributed carbapenemase bla-NDM-1 was 
being acquired by Klebsiella. We observed two dominant lineages, but neither the overall resistance 
profile nor virulence-associated factors, explain their evolutionary success. Phenotypic analysis of 
resistance shows few differences between the acquisition of resistance genes and the phenotypic 
resistance profile, including beta-lactam antibiotics that were used to treat ESBL-positive strains. 
Resistance against these drugs could be explained by inhibitor-resistant beta-lactamase enzymes, 
carbapenemases or ampC type beta-lactamases, at least one of which was detected in most, but not 
all relevant strains analysed. Complete genomes for six selected strains are reported, these provide 
detailed insights into the mobile elements present in these isolates during the initial spread of NDM-1.  
The unexplained success of some lineages within this pool of highly resistant strains, and the 
discontinuity between phenotypic resistance and genotype at the macro level, indicate that intrinsic 
mechanisms contribute to competitive advantage and/or resistance.
Coincident with the development of antibiotic therapy, there has been a steady increase in the numbers and types 
of bacterial pathogens acquiring resistance to antimicrobials, with some clades showing a propensity to spread 
globally1,2. Klebsiella pneumoniae has been particularly successful in this regard and is a member of the ESKAPE 
pathogen group that are acknowledged as causes of serious infections associated with multidrug resistance3,4. 
Before this rapid increase in drug resistance, K. pneumoniae was primarily known as a major cause of infections 
in neonates, especially in Low- and Middle-Income Countries (LMICs)5–8 and community-acquired and nosoco-
mial infections in immunocompromised patients9–11.
The population structure of K. pneumoniae was redefined recently as a species ‘complex’. This complex 
includes K. pneumoniae sensu stricto, which poses the main burden of hospital-acquired infections; K. variicola, 
which can be plant-associated12 but also causes hospital infections13–15; and K. quasipneumoniae, which were 
initially thought to be asymptomatic carriage isolates, until more recent reports highlighted their potential viru-
lence and increased drug resistance16–18. DNA sequence-based phylogenetic typing analysis of the K. pneumoniae 
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species has revealed complex, deeply branched lineages, and these data can be used to inform the epidemiological 
analysis of different high-risk, globally distributed clones19.
The acquisition of extended-spectrum beta-lactamases (ESBLs) rapidly increased in K. pneumoniae from the 
1990s, particularly in hospital isolates20,21, and was driven by mobile elements (usually plasmids) often encod-
ing several other resistance genes. The year 2009 saw the first description of NDM-1, a metallo-beta-lactamase. 
NDM-1 hydrolyzes carbapenems and is not targeted by beta-lactamase inhibitors22, thus allowing bacteria 
expressing NDM-1 to bypass the two main treatment options for ESBL-positive strains. The other known enzymes 
in K. pneumoniae conferring resistance against beta-lactamase inhibitors are ampC-type beta-lactamases and 
inhibitor-resistant beta-lactamases.
There is currently little understanding of why some K. pneumoniae sequence types are more successful than 
others. High-risk lineages in related pathogens, e.g. Escherichia coli ST131 and Salmonella enterica serovar 
Typhimurium ST313, acquired multiple antibiotic resistance determinants prior to their clonal expansions. Here, 
we describe the population structure and resistance profiles of K. pneumoniae isolated from a large hospital in 
Pakistan during routine sampling in 2010–2012. Our analysis reveals that there are many lineages that were 
prevalent at the time which have subsequently not spread more globally11, and that dominant lineages which are 
now recognised as high-risk clones did not carry NDM-1. We combined short-read and long-read sequencing 
and phenotypic resistance profiles for selected isolates, and observed NDM-1 to be unstable in some of these 
K. pneumoniae lineages. Our study again strongly emphazises the relevance of the genetic background and intrin-
sic resistance mechanisms to provide some strains with a competitive advantage within a pool of highly resistant 
K. pneumoniae population.
Results
Conserved esBL gene repertoire vs. high diversity in additional beta-lacatamse genes. The 
isolates were collected between 2010–2012 through the routine microbiological screening of bacterial infections 
in The Children’s Hospital, Lahore, Pakistan, and were pre-selected for ESBL expression through the E-test23. At 
this time, ESBL-resistant K. pneumoniae were responsible for a significant clinical burden at Lahore hospital. The 
patients ranged in age between neonates (<29 d) and 15 years, and all received at least one invasive procedure 
during their hospital stay (97% intravenous lines) as described in detail in Ejaz et al.23. ESBL-positive K. pneu-
moniae were responsible for a high number of negative outcomes (‘left against medical advice’ or death) in the 
hospital during the study period (87/214). Whilst the patient symptoms and the overall epidemiology of the strain 
collection was discussed in detail in Ejaz et al.23, we now perform a detailed genomic analysis to identify resistance 
and virulence genes, and explore whether any of these genes conferred a competitive advantage within this highly 
drug-resistant isolate collection.
Phenotypic screening of antibiotic susceptibility (Table S1) identified isolates that were negative for AmpC, 
but resistant to cefoxitin, a second-generation cephalosporin that is, contrary to other cephalosporins, resistant 
to the activity of ESBL enzymes24 (Fig. 1). To identify any lineages responsible for this resistance, and to assess 
whether a new resistance mechanism was spreading, we conducted a detailed analysis of the resistance profiles. 
We combined phenotypic analysis using the Vitek system, which facilitates measuring susceptibility to a wide 
range of antimicrobials at high throughput, with genomic analysis of candidate acquired resistance genes.
Klebsiella spp. normally harbour two chromosomally integrated enzymes related to low-level beta-lactam 
resistance. AmpH is an AmpC-related enzyme functioning as penicillin-binding protein, whereas beta-lactamases 
of the SHV, OKP or LEN family are usually present as one chromosomal copy in K. pneumoniae, quasipneumo-
niae and variicola, respectively25 (Figs 2 and S1). In addition to these well established resistance genes, we detected 
a high number of acquired resistance genes, where the extended-spectrum beta-lactamase CTX-M-15 was ubiq-
uituously present. We detected three OXA and three TEM beta-lactamase sequence variants (the TEM DNA 
sequence variants translate into identical amino acid sequences), and observed that a small number of isolates 
carried the rare VEB-5 beta lactamase. We furthermore detect several isolates with an additional copy of the SHV 
beta-lactamase family, most likely acquired on a plasmid. We detected other beta-lactam resistance genes with 
extended spectrums including the the AmpC enzymes CMY-2 and CMY-6, and the NDM-1 carbapenemases 
(Figs 2 and S1). The measured MIC values for widely-used antimicrobials of this isolate collection generally 
matched the genomically-predicted resistances (Table S1, Fig. S1). Intrinsic resistance mechanisms such as deac-
tivation of porins, upregulation of efflux pumps, or differential expression of resistance genes, might account for 
resistance in the non-matching isolates26,27.
Sensitivity was observed among a high number of isolates for cefoxitin and piperacillin-tazobactam. This is 
expected as cefoxitin is generally insensitive to ESBL24,28 (e.g. bla-CTX-M-15, which was present in all but one 
of our isolates), whereas resistance against piperacillin is widespread; in contrast, the beta-lactamase inhibitor 
tazobactam was still usually effective24,29. In most of our isolates, resistance against cefoxitin was explained either 
by the presence of the carbapenemase bla-NDM-1 which hydrolyses cefoxitin30, the bla-CMY AmpC31, or both 
(Fig. S1). Importantly, these data reveal that there was not simply a single acquisition of an additional resistance 
gene in the population leading to the extended resistance phenotype. Three isolates (HE021, HE205, HE206; 
Fig. S1) expressed phenotypic resistance that could not be explained by acquired genes. A pan-genome analysis of 
the K. quasipneumoniae lineage reveals a number of differences which might affect drug sensitivity such as trans-
posases and hypothetical proteins (likely phage-derived following comparisons to public databases), however the 
only clear genetic difference between HE205 and HE206, and closely related sensitive isolates, is a predicted iron 
uptake system (fec) that was absent from the resistant strains. However, it is unclear whether fec has any effect on 
the observed resistance, or whether other changes like differential expression of genes, for example upregulation 
of efflux pumps or downregulation of porins, leads to cefoxitin resistance in these strains.
In considering other alternative drug treatments for ESBL-positive organisms, we noted that sensitivity against pip-
eracillin/tazobactam (TZA) often coincided with lower MIC values against amoxicillin/clavulanate (Fig. S1; Table S1). 
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This is despite the fact that, based on a phenotypic sensitive/resistant evaluation, these isolates grew at drug levels 
above the defined resistance threshold, and thus were assessed as amoxicillin/clavulanate resistant. More detailed 
analysis of the encoded SHV/OKP bla genes revealed that several K. quasipneumoniae isolates (HE031, HE029, 
HE025, HE034, HE023; ST334) harboured a bla-SHV gene in addition to the intrinsic bla-OKP. The hypothesis 
that this mismatch in genotype and phenotypic resistance was plasmid-derived is supported by the plasmid rep-
licon profiles of these isolates, which differ from closely related strains lacking the additional bla-SHV (Fig. 2). 
These putatively plasmid-borne blaSHV genes encode the mutations G238S and E240K, which correlate with 
TZA resistance or TZA-intermediate sensitivity (Fig. S1)32–34. We also observed several sequences encoding the 
L35Q mutation. However, the L35Q mutation only provides a subtle increase in TZA MICs32,34,35, and no muta-
tion was found at S13036. In summary, we found four different mechanisms that confer resistance against cefoxitin 
and/or inhibitor combinations in addition to the endogenous ESBLs. These include NDM-1, CMY-2, CMY-6, and 
additional SHV copies and their combinations, as well as three strains with unexplained profiles, highlighting the 
diversity of resistance mechanisms present in our collection.
No single factor gives competitive advantage. To test whether the observed resistance patterns 
resulted from expansion of single lineages that had earlier acquired the respective mechanism, or multiple intro-
ductions into the same or distinct lineages, we analysed the data in context of their phylogenetic history. Our 
dataset included 21 different sequence types (STs)23 (Fig. 3a), with 56 isolates of K. quasipneumoniae, a species 
that was until recently thought to be less virulent than its related species, K. pneumoniae sensu stricto and K. 
variicola (Fig. 3)23. The prevalence for each ST ranged from a single to 52 isolates (ST 334), showing that the STs 
that acquired ESBL genes were not equally competitive in the hospital. These observations suggest that unresolved 
factors in the genetic background lead to higher prevalence of some lineages over others when all the isolates with 
a similar resistance profile are evaluated in the same setting.
The capsule (K) is an essential virulence factor for K. pneumoniae and, together with lipopolysaccharide 
O-antigen (O) types, used for typing. K- and O-type can be identified and assigned based on their respective 
operons in the genomes. Recent work37,38 highlighted the considerable diversity found among different K. pneu-
moniae capsule types39. This phenomenon is also reflected in our collection, where we observed a different cap-
sule type for almost each sequence type, and no single type correlating with more dominant lineages (Fig. 3b, 
Table S2). This argues against any one capsule type itself conferring a competitive advantage in this setting, but 
rather that either multiple capsule types are equally advantageous, and/or that some combinations of capsule type 
and genotype are more competitive in a clinical setting that others.
Figure 1. Resistance profiles. (a) Vitek data showing the number of strains read as sensitive, intermediate 
or resistant against the respective antimicrobial. (b) Isolates resistant against cefoxitin or carbapenems were 
assessed for the presence of genes expected to confer this resistance, highlighting a small gap of strains with 
non-predicted resistance mechanisms.
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In contrast to capsule loci, there was less diversity of LPS O-antigens with two main types in these ESBL pro-
ducing isolates (Fig. 3c). While other global studies37,40 observed a combination of O1 (52%/26%; from Follador 
et al., and Pennini et al., respectively), O2 (16%/36%) and O3 (15%/13%) as main LPS types37,40,41, we observed 
Figure 2. Antimicrobial resistance (AMR), plasmid replicons and virulence genes, and K- and O-type. 
The guide tree is based on roary, the branches leading to K. pneumoniae and K. quasipneumoniae are not to 
scale to facilitate visualisation; and shows the diversity of capsule and O-antigen type, which correlate with 
sequence types (one sequence type usually shares the capsule- and O-antigen combination). The predictions of 
AMR genes, virulence genes and plasmid replicons was performed using ariba43, a mapping-based approach 
independent of assemblies. The guide tree is based on roary as in Fig. 1 where the branches leading to K. 
pneumoniae and K. quasipneumoniae are not to scale to facilitate visualisation.
www.nature.com/scientificreports/
5Scientific RepoRts |          (2019) 9:2392  | https://doi.org/10.1038/s41598-019-38943-7
O1 (44%) and O5 (38%; vs. 6%/1% in the global studies) as the most common. The high prevalence of O5 was due 
to a single lineage expansion, one of the two very dominant lineages was O5 (ST334), whereas the other one was 
O1v1 (ST15). The differences in O-antigen abundance of different studies are highly relevant as O-antigens are 
often considered vaccine targets in K. pneumoniae.
Virulence factor distribution. The genes encoding the siderophores aerolysin and yersiniabactin were only 
detected in K. pneumoniae isolates, in accordance with a previous large-scale study investigating 2499 isolates42 
which also reports their absence in K. quasipneumoniae. Forty-one isolates, representing 33.6% K. pneumoniae, 
carried the yersiniabactin determinant, and 42 K. pneumoniae (34.4%) carried aerobactin. Only 7 of these isolates 
(5.7%) encoded both siderophores42 (Fig. 2), and no salmochelin or colibactin encoding genes were identified.
The profiles present in our strains include six different types of yersiniabactin using the classification of yersin-
iabactin (ybt) and their associated mobile elements (Kp integrative conjugative element ICEKp) by Lam et al.42. 
These ybt loci were present in eight sequence types. Our collection also included a less common combination of 
ybt8 with ICEKp3 (ST423). In addition, we found one sequence type (ST48) with three different ybt-ICE variants 
(Fig. 2; ICEKpn11 + ybt15, ICEKpn4 + ybt10, ICEKpn5 + ybt14), suggesting independent acquisition of different 
siderophore types even within a confined setting.
We also noted a high number of genes predicted as pseudogenes by ariba43, especially multiple occur-
rences of the virulence gene rmpA2 as pseudogene, which is one of the capsule upregulators and diagnostic for 
Figure 3. LPS O-antigen, capsule and sequence types in this study. (a) Two main (ST15, ST334) sequence types 
dominate the collection, followed by several medium-abundance (e.g. ST45, ST336) types and a high diversity 
of low-abundance sequence types. (b) The capsule types almost share almost exactly the same level as diversity 
as the sequence types, with a different capsule type associated with sequence types; whereas the O-antigen types 
(c) are as expected less diverse, but dominated through the commonly as less diverse perceived type O5.
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hypervirulent K. pneumoniae (Fig. S2a). The rmpA2 genes were all disrupted through a single-nucleotide addi-
tion or deletion in either a poly-G or poly-A region in this gene causing a frameshift as described previously44 
(Fig. S2a), and the encoded potential for random slip-straind misrepair to bring rmpA2 into frame and increase 
capsule production. RmpA and aerobactin are indicative of the presence of the K. pneumoniae virulence plasmid 
found in hypervirulent strains45–48, and we therefore compared the typical K. pneumoniae virulence plasmids, 
indicative in particular of the hypervirulent clonal group 23 (CG23), with our data. We performed comparisons 
against the plasmid pSGH10, which is representative of the hypervirulent clade CG2348. This comparison showed 
that sequences similar to the pSGH10 plasmid are present in two main STs in our collection but that both STs lack 
salmochelin and other elements of the plasmid pSGH10 (Fig. S2b)49,50. There was also variability of which regions 
of the plasmid were conserved within the STs in our study, again highlighting the highly dynamic and plastic 
nature of K. pneumoniae genomes.
The plasmid background of NDM-1. To identify the number of different plasmids that were present in 
our dataset, and to assess how many are still in circulation (e.g. reported in the recent literature), we performed 
long-read sequencing of representative isolates, using Pacific Biosciences (PacBio) technology (Tables 1, S2). 
Some NDM-1 genes detected in Illumina reads were not confirmed by PacBio sequencing, and were only detected 
with low read coverage (Table 1 and Fig. S3). Hence, we performed additional MIC tests for meropenem (E-tests, 
see methods; Table 1) using cultures generated after DNA extraction for sequencing. This phenotypic analysis 
confirmed that, where only lower read coverage for NDM-1 was observed in the earlier Illumina data, the bacteria 
were meropenem-sensitive indicating either loss of the plasmid carrying NDM-1 or of a highly mobile cassette 
carrying NDM-1. Even though we cannot exclude contamination during the multiplexed short-read sequencing 
run or the earlier stages of the sample preparation, the unstable nature of NDM-1 has been observed previously in 
several independent reports, where loss can occur after two generations of laboratory subculture, and even under 
meropenem selection51–53. The putative loss of the entire plasmid carrying NDM-1 in part of our samples, or at 
least a larger transposable cassette, is further supported by the observation that several resistance genes that were 
predicted at equally low abundance in Illumina sequencing, were absent from the PacBio assemblies, indicating 
an unstable plasmid carrying these resistances, which included NDM-1 (Fig. S3).
Incompatibility group F and H plasmids were fixed in the population across all sequence types, with IncN and 
IncR only rarely observed; this is in agreement with a large comparative study describing IncFII, IncA/C, IncL/M, 
and IncI1 as the main resistance-carrying Inc types in Klebsiella54 (Figs 2 and 4a). Two of the plasmids resolved 
by long-read sequencing (strains HE016 and HE066) show the original, more complete cassette including the 
GroEL/S from the Acinetobacter construct55 (Fig. 4b,c), whilst in one case (HE125) a smaller portion of this gene 
region is conserved (Fig. 4c); this variation in the different genes surrounding NDM-1 has been described in 
other studies55–58.
Strain MIC (Meropenem) NDM-1 coverage
HE006 (14893_8#74) 64 75.0
HE007 (14893_8#75) 32 83.8
HE021 (14893_8#89) 2 Not Detected
HE016 (14893_8#84) 64 59.3
HE019 (14893_8#87) 64 79.1
HE121 (14936_2#2) 32 105.4
HE122 (14936_2#3) 16 49.4
HE065 (14936_3#41) <1.25 Not Detected
HE125 (14936_2#6) 32 73.3
HE128 (14936_2#9) 32 43.4
HE001 (14893_8#69) 16 8.1
HE035 (14936_3#11) 4 Not Detected
HE063 (14936_3#39) 16 6.2
HE055 (14936_3#31) 16 Not Detected
HE060 (14936_3#36) 64 44.7
HE061 (14936_3#37) 64 47.1
HE062 (14936_3#38) 64 53.8
HE213 (14936_2#94) <1.25 Not Detected
HE064 (14936_3#40) 64 52.9
HE066 (14936_3#42) 64 56.3
HE100 (14936_3#76) 64 43.5
HE117 (14936_3#93) 64 53.9
Table 1. Detection of carbapenemase using minimum inhibitory concentration and gene prediction (ariba read 
coverage).
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Comparison of ST15 isolates from Pakistan with a reported ST15 outbreak in Nepal. ST15 is 
an example of a widespread problematic K. pneumoniae clade. Given the relative geographic proximity between 
Pakistan and Nepal, we analysed the relationsips between the two ST15 lineages reported in Nepal59,60 with those 
isolates in our collection (Table S3). We assessed the presence or absence of genes via a pan-genome analysis of 
a subset of isolates, as well as mapping of the short read data for the same isolates against a PacBio-sequenced 
reference sequence (accession number CP008929; Figs 5 and S4) from the Nepal outbreak59. The phylogeny indi-
cated that the ST15 population from Lahore was comprised of several subgroups, and differences indicated by 
longer branches correlated with changes seen in the mapping results (Fig. S4). Even within the tight group of the 
isolates from Lahore, at least three different sublineages had emerged. Each of these sublineages lack one, two or 
three regions found in the reference strain from Nepal (Fig. S4). A detailed overview of resistance, virulence gene 
profiles, plasmid replicons and surface determinants (capsule and O-antigen type) is provided in Fig. S4, and 
includes part of the Type VI secretion system as well as cellulose biosynthesis. Analysing the capsule operons, we 
observed the same novel capsule type as described in the Nepal isolates60 (Fig. 5), further highlighting that ST15 
appears to be spreading throughout the South Asian subcontinent.
Figure 4. Complete plasmid repertoire of selected isolates. (a) The plasmids, their replicons and sizes as 
predicted after pacbio sequence analysis are shown for the respective isolates. (b) A close-up of the original 
NDM-1 cassette96. (c) The three plasmid contigs from the PacBio assemblies of HE016, HE066 and HE125 
which contain the NDM-1 gene, were compared against a plasmid encoding the original cassette as described 
for Acinetobacter55. This shows the different levels of conservation of the cassette, whilst nothing else of the 
original plasmid can be found.
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In contrast, a comparison of the plasmid content showed almost entirely different compositions of plasmids in 
Nepal and Lahore, Pakistan (Figs 5 and S5). Only one of the Nepal plasmids (plasmid A) is partially conserved in 
the isolates we examined (Fig. S5), in accordance with the absence of NDM-1 (Fig. S5). Several gene clusters from 
the Nepal outbreak plasmids are conserved and likely to be encoded on different plasmids, including (Nepal plas-
mid A) lacIZY, phosphate transport (phnD/E ptxD); arsenic (ars), copper (pco), silver (sil) and cation (cus) efflux 
systems, as well as plasmid maintenance proteins from this plasmid. Only sparse similarity can be found with 
other plasmids (e.g. Nepal plasmid C streptomycin resistance), in accordance with the different virulence and 
resistance profiles of the two hospital lineages. A subgroup of the ST15 isolates from Pakistan (HE080, HE098, 
HE139, HE157, HE158) did not share the genes from plasmid A in Nepal, which can also be seen by their differ-
ent virulence factor profile (Figs 5, S4 and S5).
Discussion
The K. pneumoniae isolates described in this study represent routinely collected samples in a Pakistan hospital 
of the K. pneumoniae species complex over an extended period23. The main burden of global clinical isolates in 
hospital strains is usually associated with K. pneumoniae sensu stricto. There were two highly prevalent STs, and 
one of these was K. quasipneumoniae subsp. similipneumoniae, a subspecies that was previously thought to be less 
Figure 5. Comparison of the ST15 isolates from an outbreak in Nepal and Pakistan. Plasmid replicons, 
resistance genes and virulence genes were predicted by ariba; the tree is a whole-genome tree after removing 
recombination with gubbins against the reference strain from Nepal (CP008929.1).
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clinically important (Fig. 2)23. The major K. quasipneumoniae sequence type (ST334) has been rarely observed 
in other studies (e.g. 1/25061; 1/16762; 1/32863; 2/19864), but was common in Lahore – we found 52 isolates (44 if 
excluding ST variants) all originating from bloodstream infections, representing 29.2% (24.7%) of samples inves-
tigated. There is however very little data on K. pneumoniae diversity from the region, and it is unclear whether 
the expansion of ST334 was an unusual occurrence, or whether this ST is still dominant in the area. Given its 
similarity to K. pneumoniae in standard diagnostics, K. quasipneumoniae numbers are very likely underestimated 
in routine testing65.
With the continuous loss of effective antimicrobials and the lag in the development of new ones being released, 
antibody-based treatments should be considered and have support through governments and global health pro-
grams66,67. There are challenges associated with immunoprophylaxis against Klebsiella infections as there is no 
single prevalent capsule- or O-antigen type. Two large-scale analyses of global datasets including all three spe-
cies identified serotypes O1, O2 and O3 in 80%/75% of hospital infections37,40. We observed a high number 
of non-O1/O2 types in our collection, and the increase of genomic and functional studies of O-types in the 
past years led to an increase in recognised LPS diversity. The diversity and distribution is of high importance as 
O-antigen has often been investigated as a potential target for an anti-Klebsiella vaccine, as only few O-antigen 
serotypes are known, in contrast to the considerable diversity in capsule types37,38. However, the lack of apparent 
correlation to disease severity37 and LPS type indicate that if an O-antigen targeted vaccine were introduced, 
switches to non-vaccine targeted LPS serotypes or the emergence of new serotypes might occur once immune 
pressure is applied68,69.
Given the reported association of the siderophore yersiniabactin with disease, we tested whether a correlation 
existed between siderophores and patient outcome, but neither yersiniabactin nor aerobactin were significantly 
associated with negative or positive events (death or discharged), in contrast to a recent description of high 
mortality with a reduced virulence factor repertoire of ST1170 (details Table 2). We observed a similar prevalence 
of aerobactin and yersiniabactin in our population, and neither of these was associated with higher number of 
isolates which could indicate competitive advantage. Both were present only in K. pneumoniae, and relatively few 
strains (7; 5.7%) encoded both siderophores. This analysis, showing parts of the virulence plasmid as well as high 
levels of resistance in the same strains, suggests that the evolutionary convergence between virulent and resistant 
strains was already occurring within these historical isolates63. Other studies have also suggested that the accu-
mulation of virulence factors is an ongoing process in K. pneumoniae, and more work needs to be done in longi-
tudinal studies to monitor the changes of the virulence potential of sequence types over time71. This is particularly 
relevant given recent observations of high mortality associated with strains with reduced virulence potential70.
The collection is derived from a time (2010 to 2012) where carbapenem resistance was still at comparatively 
low levels and NDM-1 had only recently been introduced into the K. pneumoniae population, whereas now we 
see very high prevalence in LMIC as well as high-income countries2,26,27. Even though the KPC carbapenemase 
enzyme was described first in 1996 in the USA72, it spread comparatively slowly but has become highly prob-
lematic in the American continent and southeast Asia (China, Taiwan, Singapore)56. NDM-1 was first reported 
in 200822, but spread rapidly within the Indian subcontinent, and across all continents by 201073,74. Our dataset 
contains several lineages with NDM-1, however these did not become globally spread high-risk lineages in the 
subsequent years. Acquisition of an NDM-1 plasmid per se is neither a sign that the plasmid will spread stably 
with the population, nor that this lineage has a major advantage over all carbapenemase-negative lineages, which 
likely reflects intrinsic factors that need to be present to provide an NDM-1 positive lineage a competitive advan-
tage over other ESBL-positive lineages as observed in Nepal. The apparent instability of the NDM-1 locus in the 
isolates we examined, most likely through plasmid instability, suggests that laboratory analysis of this important 
resistance must be conducted carefully.
Monitoring resistance to inhibitor-based treatments is crucial as this combination treatment is a common 
clinical response to ESBL infections29, and there are ongoing efforts to develop inhibitors against beta-lactamases 
and more recently also carbapenemases75–77. There is considerable subtlety in the evolution of drug resistance, 
and especially for beta-lactams a variety of activity spectra across resistance enzymes in one strain is likely to be 
of importance, as enzymes with lower activity spectra are often more resistant to inhibitors than broad-spectrum 
ESBL enzymes78. Detailed analyses, including the fitness cost of resistance genes as indicated by the unstable 
nature of NDM-1 or, as contrasting example, the rapid spread and fixation of CTX-M-15, are crucial to our 
understanding of the different mechanisms of resistance and their fixation in a population.
Siderophore
Outcome
Discharged TotalDeath
Yersiniabactin+ 16 26 42
Yersiniabactin− 34 75 109
Total 50 101 151
p-valuea pchi = 0.5388
Aerobactin+ 13 22 35
Aerobactin− 37 79 116
Total 50 101 151
p-valuea pchi = 0.709
Table 2. Testing outcome versus presence of yersiniabactin or aerobactin. aP-value determined via a chi-square 
test of independence using the R function chisq.test(input matrix).
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Materials and Methods
strain collection. The strains were derived from routine diagnostic bacterial cultures in the Microbiology 
Department of The Children’s Hospital & The ICH Lahore, Lahore, Pakistan, during 2010–2012, where 13% of all 
laboratory-positive samples were K. pneumoniae. The strains were pre-selected for ESBL resistance, and a detailed 
description of the infections in the hospital during the time as well as specific data on patient symptoms and other 
metadata regarding the strains analysed here can be found in Ejaz et al.23. The study was ethically approved by 
the institutional review board of The Children’s Hospital, Lahore under No. 1625/PH&I. The studies were com-
pliant with the ethics approval granted by the Institutional Review Board of the Lahore Children’s Hospital, all 
the methods were performed in accordance with the standard ethical guidelines and do not include any human 
or animal trials.
pacBio DNA preparation and sequencing. DNA from overnight cultures was isolated by Phenol:Chloroform: 
Isoamyl Alcohol (25:24:1) and Chloroform:IAA (24:1) extractions using Phase-lock tubes (Qiagen) and re-dissolved 
in 10 mM Tris pH 7.4 buffer. Sequencing was performed on the PacBio RSII using P6/C4 sequencing chemistry, 
the library was prepared using the SMRTbell Template Prep Kit 1.0. Filtered sub-reads were generated with the 
pacbi-smrt software, and assembled with canu v1.179. The assemblies were then circularised using circulator v1.5.380 
with canu as assembler, and polished with unicycler-polish v0.4.081 and the Illumina reads of the respective sample. 
HE016 gave better results in assembling with the unicycler-hybrid assembler v0.4.0 combining the PacBio data with 
the Illumina reads81, and was subsequently circularised and polished as above. All assemblies were then annotated 
with PROKKA v1.1182.
Bacteria Mapping and Variant Detection. Mapping was performed against the chromosome of Klebsiella 
pneumoniae NTUH-K2044 (AP006725), a published whole genome from an outbreak in Nepal59 and HE196 (this 
study). Sequence reads were mapped against the reference genome as indicated using SMALT83 (v0.7.4) to pro-
duce a BAM file. Variation detection was performed using samtools mpileup v0.1.19 bcftools v0.1.19 to produce 
a BCF file of all variant sites.
pan-genome analysis. The samples as indicated in the respective experiments were assembled and anno-
tated as described above, and the GFF3 files generated by PROKKA v1.1182 were used as input for the pan-genome 
pipeline Roary50 (v3.7.0) with a BLASTp percentage identity of 90% and a core definition of 99%. This gives a 
core gene alignment of 3486 genes for all strains from this study (Figs 1, 2). The core gene alignment was gener-
ated with mafft v7.20584; SNPs were first extracted using snp-sites v2.3.285, and then a maximum likelihood tree 
with RAxML v8.2.886 was calculated. For the ST15 comparison, the pan-genome was calculated as described 
above, and gene presence/absence analysed further using R v3.4.2 and the resulting presence/absence matrix and 
phandango87.
phylogenetic analyses. Trees were calculated using RAxML86 (v8.2.8) with the time-reversible GTR model 
and 100 bootstrap repeats. Tree demonstrations were prepared in itol88, coverage plots were generated using 
bedtools genome coverage89 and displayed using the R package ggplot v2.2.190. For whole-genome mapping trees, 
recombinant regions were removed using Gubbins91 (v1.4.9) and a maximum likelihood tree calculated with 
RAxML to obtain bootstrap support values, as described above, and sites with more than 5% N were not consid-
ered in the tree calculation.
Gene content analysis. For the determination of the antibiotic resistance profile, the virulence factor 
profile and plasmid types, we used ariba. The resistance, virulence and plasmid profiles were matched against 
the modified version of ARG-ANNOT92 available at the SRST2 website (https://github.com/katholt/srst2/tree/
master/data; download date 02.10.2016), a dataset of virulence factors obtained from the Klebsiella-specific 
BIGSDB (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html; download date 22. 02. 2016), and the PlasmidFinder 
database as implemented in ariba v2.10.093,43. Sequence gene profiles and types were determined using MLST 
check94 comparing assembled genomes against the MLST database for Klebsiella pneumoniae (pubmlst.org/
Klebsiellapneumoniae/). For further resistance determinants (SNP- based or porin inactivation), a database 
with the genes of interest was created as outlined in the ariba manual pages. The assignment of bla-SHV alleles 
was controlled based on amino acids using the beta-lactamase database http://www.laced.uni-stuttgart.de. 
Yersiniabactin and ICE alleles were annotated using kleborate42 (https://github.com/katholt/Kleborate). Capsule 
and LPS O-antigen was annotated using kleborate and a custom database of LPS O-antigens37. The assignment 
to O3 subgroups was updated based on recent nomenclature (O3l/s; now a/b/c) using the online tool Kaptive41 
(http://kaptive.holtlab.net/).
Minimum inhibitory concentrations (MIC) measurements. All isolates were analysed using the 
VITEK 2 system (bioMérieux, UK). In brief, suspensions of colonies were made in 0.45% saline solution from 
growth on iso-sensitest agar (Thermo Scientific Oxiod, UK), adjusted to a turbidity equivalent to that of a 0.5 
McFarland standard and used to load the test cards, using manufacturer’s instructions. The Enterobacteriaceae 
AST-N350 cards was automatically filled, sealed and inserted into the VITEK 2 reader–incubator module (incu-
bation temperature 37 °C), and fluorescence measurements were performed every 15 min for up to 18 h. For 
detailed analysis of several NDM-1 containing strains, the MICs for meropenem were also assessed manually 
following the protocol of Wiegand 200895 (Table 1).
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Data Availability
Details on strains and accession numbers can be found in Table S1 (Vitek resistance data), Table S2 (accessions 
and further information on isolates from Pakistan) and Table S3 (additional published strains used for the anal-
yses). Data provided for the Pakistan samples includes accessions for raw sequence data as well as assemblies of 
both Illumina and PacBio sequenced genomes and patient metadata. All relevant data is in the manuscript and 
supporting material, alignment and tree files are available for download at figshare https://figshare.com/s/cdadd-
b659a6e178102df.
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